Boston Scientific Reports 20.9% Revenue Growth in Q1 2025 Financial Results
US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report,...
Finanical Reports
Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
Bio-Thera Solutions Reports 5.44% Revenue Growth in 2024 Driven by Biosimilar Sales
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced its 2024 financial results, recording RMB 743.17 million (USD...
Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals
Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...
Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector
China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...
MicroPort Endovascular Reports 1.61% Revenue Growth in 2024 with Strong Profit Increase
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) released its 2024 financial report, showing a...
Luye Pharma Group Reports 2024 Revenue Dip Despite Growth in Product Sales
China-based Luye Pharma Group (HKG: 2186) announced its 2024 financial performance, recording RMB 6.061 billion...
Hengrui Pharmaceuticals Reports 22.63% Revenue Growth in 2024 with Strong Innovative Drug Sales
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) released its 2024 financial report, recording RMB...
Akeso Biopharma Reports 53% Revenue Decline in 2024 Despite Growth in Product Sales
China-based Akeso Biopharma (HKG: 9926) released its 2024 financial report, recording RMB 2.124 billion (USD...
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total...
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362...
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...